Subsequently, a phase III clinical study (PALOMA-2) confirmed a benefit in progression-free survival in patients that were treated in first-line with palbociclib plus letrozole for ER-positive/HER2-negative advanced breast cancer [353]. Here, ESR1 is linked to breast carcinoma.